DMAC Form 4: 450,000 CMO stock options, vesting over time

Rhea-AI Filing Summary

DiaMedica Therapeutics (DMAC) reported a Form 4 for its Chief Marketing Officer showing a grant of stock options to purchase 450,000 shares at an exercise price of $4.58 per share on 08/11/2025. The options expire on 08/10/2035 and were reported as directly owned following the transaction.

The filing states a time-based vesting schedule: 112,500 options vest on the one-year anniversary of the grant date, and the remaining 337,500 vest in twelve equal quarterly installments starting three months after that one-year mark, conditioned on continued service.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Krop Julie

Role Chief Marketing Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	450,000	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 450,000 shares (Direct)

Footnotes (1)

1. [object Object]

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/03/2025 - 04:32 PM Learn about SEC filing dates

FAQ

What did DiaMedica (DMAC) disclose in this Form 4?

A grant of 450,000 stock options to the Chief Marketing Officer at an exercise price of $4.58 per share on 08/11/2025.

What is the exercise price and expiration of the DMAC CMO options?

The exercise price is $4.58 per share, and the options expire on 08/10/2035.

How do the 450,000 DMAC options vest?

112,500 vest on the one-year anniversary of grant; the remaining 337,500 vest in 12 equal quarterly installments starting three months after that anniversary, subject to continued service.

How many derivative securities were owned after this transaction?

The filing lists 450,000 derivative securities beneficially owned following the reported transaction, held directly.

Who is the reporting person in the DMAC Form 4?

An Officer of DiaMedica, serving as Chief Marketing Officer.

Was there a purchase price for the option grant itself?

The reported price of the derivative security is $0; the exercise price to buy shares is $4.58.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Krop Julie

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MN 55305

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Marketing Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$4.58	08/11/2025		A		450,000		(1)	08/10/2035	Common Stock	450,000	$0	450,000	D

Explanation of Responses:

1. 112,500 shares vest on the one-year anniversary of the grant date, and the remaining 337,500 shares vest in twelve equal, or as nearly equal as possible, quarterly installments commencing three months after the one-year anniversary of the grant date; provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.

	/s/ Joshua L. Colburn, attorney-in-fact	11/03/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.